Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Neurology | Pharmacy | Institutional

Back to Journal Articles

Patients on Gilenya for MS May Require Extended Monitoring

Last Updated: May 14, 2012.

 

FDA recommends keeping watchful eye on heart rates

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Based on the report of a patient who died after taking one dose of the multiple sclerosis drug Gilenya (fingolimod) and on clinical trial data, the U.S. Food and Drug Administration is recommending extended monitoring for certain patients taking this drug, according to a May 14 Drug Safety Communication issued by the agency.

MONDAY, May 14 (HealthDay News) -- Based on the report of a patient who died after taking one dose of the multiple sclerosis (MS) drug Gilenya (fingolimod) and on clinical trial data, the U.S. Food and Drug Administration is recommending extended monitoring for certain patients taking this drug, according to a May 14 Drug Safety Communication issued by the agency.

Although a cause of death was not identified, the patient in question, who also had extensive brainstem MS lesions, died within 24 hours of taking the drug. This prompted the agency to re-evaluate clinical trial data on the effects of the drug on heart rate and blood pressure.

The agency notes that Gilenya usually lowers a patient's heart rate within six hours of the first dose, but this effect can occur up to 12 to 20 hours after the first dose. Based on these findings, the FDA suggests monitoring patient heart rates longer than six hours if they experience a heart rate below 45 beats per minute, or if they have pre-existing conditions or take other drugs that could further slow heart rate.

According to the FDA, "in light of the findings of the clinical trial data and postmarketing data, including all reported deaths of cardiovascular or unknown origin, [we have] revised the Gilenya drug label with specific recommendations for monitoring patients and with new contraindications for use of Gilenya in certain patients."

More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: American Psychiatric Association, May 5-9, 2012 Next: PET More Sensitive Than CT for Merkel Cell Carcinoma

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.